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In the August 2014 issue of Contact Lens and Anterior Eye, Kate L. Johnson [1] asked “are we being 
myopic about myopia control?” In this thought-provoking editorial, Kate Johnson identiﬁed the 
hesitation to fully embrace myopia management amongst her clinical colleagues, and the frustration 
that this caused her academic colleagues. Is her portrayal of myopia control resistance in clinical 
practice a fair representation of myopia control worldwide?  According to a global survey 
investigating myopia management attitudes and strategies in clinical practice [2] published in this 
issue, the answer is ‘yes’. 
An internet-based questionnaire, containing questions regarding awareness of myopia prevalence, 
and perceived efﬁcacy and uptake of myopia control strategies, was created by the myopia group at 
Aston University, and distributed by the BCLA and other professional bodies to eye-care 
practitioners around the world [2]. Although practitioners are largely aware of the increasing 
prevalence of myopia and the management strategies available, the majority (67.5 ± 37.8%) 
prescribe single vision spectacles or contact lenses as their primary mode of myopic correction. This 
is the ﬁrst survey of its kind to evaluate worldwide myopia management and, although the results 
are unsurprising, they conﬁrm our suspicions that the information from scientiﬁc literature is not 
translating to clinical practice. The results of the survey call for clear guidelines for myopia control. 
Myopia prevalence has increased throughout the world, particularly in East   and South-East Asia, 
where it has reached epidemic levels. However, it is as prevalent as 20-50% in US and Europe. 
Genetics of  a child are known to  pre-determine their subsequent  refractive status,  for   example,  
children with  two myopic parents are  six  times more likely to  become myopic themselves than 
children with one or  no myopic parents [3]. Despite this, genetics alone cannot account for the rapid 
increase in myopia prevalence. Several environmental mechanisms have been proposed including: 
insufﬁcient/inaccurate accommodative response, excessive time spent reading and/or being 
indoors. Furthermore, animal work has suggested that a relatively hyperopic peripheral refraction 
drives the excessive eye growth responsible for  myopia development/progression. 
Despite the large body of research dedicated to understanding the mechanism of excessive eye 
growth, the exact mechanisms responsible for myopia development and progression are not yet 
fully understood, presumably due to the multifactorial nature of the disease. In the absence of a 
single causative factor, several intervention strategies have been investigated, the most promising of 
which involve contact lens wear. 
We know, from the global myopia management survey [2], that single vision spectacles and contact 
lenses are the most frequently prescribed modality.  It  has  been suggested that  this approach 
increases relative peripheral hyperopic defocus, which, according to  animal work, stimulates eye  
growth. Other authors, however, question that peripheral refraction is the primary driver of eye 
growth, as they reported that some children do not display relative peripheral hyperopia before 
becoming myopic. Regardless of whether, or not, you buy into the peripheral refraction theory, it is 
unlikely that single vision spectacles or contact lenses mitigate myopia onset or progression. 
Under-correction, the deliberate reduction of the myopic correction, was hypothesised to reduce 
accommodative demand and induce myopic defocus, which should prevent eye growth. On the 
contrary, under-correction has been found to accelerate the rate of myopia progression. 
Pharmaceutical therapies, such as atropine and pirenzepine, have proven to  be  highly effective. 
Atropine in particular has the ability to reduce myopia progression by up to 77% [4]. Despite this 
promising ﬁgure, a lack of consensus exists for the mechanism of action, the optimum effective dose 
which minimises unwanted side-effects and the  inevitable rebound effect following the cessation of  
treatment.  Another obstacle exists in that neither atropine nor pirenzepine are licensed for myopia 
control, which is likely  to   cause further  reluctance  to   prescribe off-label to paediatric patients. 
Furthermore, low-dose preparations (<0.5%) are not commercially available. 
It has been established that increased time spent outdoors has a protective effect against myopia 
development/progression. It is not yet clear why outdoor activity has this effect but it  is postulated 
that bright light triggers the release of dopamine, a retinal transmitter  which  is   believed  to   
prevent  eye   growth.  Other theories suggest that the sunlight itself could play a role, increasing 
exposure to  vitamin D, which has been shown to  reduce eye growth.  Finally, the  increased viewing 
distances and the  high luminance levels afforded by outdoor activities diminish accommodative 
demand and reduce pupil diameter/increase depth of focus, thereby increasing retinal image 
quality. 
Multifocal spectacles and contact lenses have been shown to reduce myopia progression by 
reducing hyperopic blur brought about by accommodative lag. Multifocal contact lens designs have 
been more effective than spectacle lens designs. This is thought to be related to the consistency of 
near portion alignment and wearing time. In this issue Pauline Kang and colleagues investigate the 
changes in visual function in these multifocal soft contact lenses when they are worn by young 
adults [9]. 
Orthokeratology was introduced to eliminate refractive error or to  reduce it  to  a  sufﬁciently small 
degree that the patient can function without  spectacles or  contact lenses for  most of  the waking 
day,  however in  recent years, it  has   been shown to  be effective in  the prevention of  myopia 
progression. Although the mechanism by which orthokeratology reduces myopia progression has  
not been ﬁrmly established, it is widely assumed that the mid- peripheral thickening, brought about 
by  the  re-distribution  of epithelial cells   as  a  result of  the central ﬂattening of  the lens, increases 
the power of  the mid periphery,  effectively reducing peripheral   hyperopic  defocus.  
Orthokeratology  studies   have yielded consistent  levels of  myopia retardation  of  around 50% [2].   
Despite the  efﬁcacy of  orthokeratology,   and the  obvious lifestyle beneﬁts  it  offers, it  only 
constitutes  1% of  new CL ﬁts worldwide. This is presumably due to concerns about contact lens 
related complications, however the risks of ocular disease in later life due to myopia are greater 
than the risk  of severe contact lens complications. The  article by Lee Jong  Soo in this issue of 
Contact Lens and Anterior  Eye examines the effect of  orthokeratology in patients with myopic 
regression after refractive surgery, another potential beneﬁt for  this lens modality [10]. 
Non-pharmaceutical myopia control has been shown to reduce myopia progression by between 20 
and 50% [2]. Although on the face of it, these ﬁgures appear modest, recent papers have put these 
values  into  context.  Brennan [5]   predicted that a 33% reduction in myopia progression would 
reduce the frequency of myopia >-5D by  73%. If the myopia reduction increased to 50%; the 
frequency of myopia >-5D  was reduced to  90%. These are powerful statistics that strengthen the 
case for adopting myopia control. 
All too often, myopia is regarded as a minor inconvenient correctable refractive problem, which only 
becomes pathological when it exceeds an arbitrary cut-off of -6D [6].  Myopia <-6D is traditionally 
considered to be ‘physiological’, however Flitcroft [6] challenged this view by suggesting that there is 
no such thing, as all myopia has  the potential to become ‘pathological’. Myopia within the so-called 
‘physiological range’ represents  a  risk   factor  for ocular disease that is comparable with the risks 
associated with hypertension for cardiovascular disease. The myopia risks for glaucoma and cataract 
were also   comparable with the risks of stroke from smoking >20 cigarettes a day.  For retinal 
detachment and myopic maculopathy, myopia carries a risk  far in excess of any identiﬁed 
population risk  factor for cardiovascular disease. When you  look  at it from a public health 
perspective, it seems negligent not to attempt to reduce myopia progression as the odds ratio for 
developing ocular complications increases sharply with each dioptre of myopia. 
According the myopia global myopia management  survey [2], the most common reasons 
practitioners gave for  not adopting myopia control strategies related to concerns about efﬁcacy, 
safety and cost.  Those practitioners  who only prescribed single vision spectacles or  contact lenses 
reported that there was inadequate information available to  them. 
The myopia management day   at the 2015 BCLA Clinical Conference in Liverpool provided  delegates  
with  an   excellent opportunity to  appreciate the pros and cons of each myopia intervention 
strategy. The session climaxed with an expert panel debating the future of myopia control. The panel 
contained leading myopia researchers from around the world, who presented the cases for each 
intervention strategy.  Organisers of other clinical conferences have also acknowledged the 
importance of  myopia control, and placed myopia researchers/experts centre-stage. Although this is 
a positive step in getting the message across to the pro-active clinicians at the cutting-edge of the 
profession in attendance, it is not reaching other clinicians who do not attend clinical conferences or   
engage  with  the  scientiﬁc  literature. As the majority of clinicians fall into the latter category, is  it 
any  wonder that resistance to  engage in  myopia control is commonplace? 
Other papers in this issue of Contact Lens and Anterior Eye could also show potential in the  realm  
of   myopia  control.  Anisa Mahomed et al show how lenses could be manipulated to release 
pharmaceuticals into the eye, such as low dose atropine [11]. Scleral lenses as reviewed by Walker 
and colleagues and Sarah La Porta Weber could provide even better stability of lens optics than soft 
design and so may have a potential role in  myopia control [12,13].  Minimising dry   eye   effects 
such as   those affected by hormone replacement investigated by Li Hu and co-workers is essential to 
compliance with contact lens treatment modalities [14].  Perhaps light transmission and assessed by 
José  M Artigas could contribute to  the outdoor environmental myopia progression retardation 
effects [15].  Who knows, future research may identify Traditional Chinese Medicine herbs such as   
those examined by Maureen Boost,  may prove beneﬁcial [16]. 
As the global myopia management survey [2]  suggests, clear clinical management guidelines would 
be useful so that all myopic patients can  be  managed consistently  and effectively, decreasing their 
relative risk   of  progression and/or complications and increasing their quality-of-life. The UK Myopia 
Consortium, which is led by Dr Nicola Logan, Senior Lecturer at Aston University, and includes 
myopia researchers from across the UK, is currently working towards this goal. Aston University will 
also host the 2017 
International Myopia Conference (IMC), a biennial research conference attended by world-leading  
myopia researchers.  The IMC will showcase the latest opinion on the mechanisms behind myopia 
development/progression, present further results from existing myopia interventions, and possibly 
introduce novel intervention methods. 
Advice for adopting myopia control in your practice 
When: now, even though we do not fully understand the mechanisms of some of the treatment 
strategies, and the success rate is not 100%, the evidence shows simple strategies will have an effect 
in reducing the risk  of myopic complications [6]. 
Who: all progressing myopes regardless of their baseline level of myopia. Also, children who have 
low levels of hypermetropia (>+0.75D) at age 6, are more likely to become myopic [7]. It might be 
prudent to intervene before this occurs. 
How: within the scope of refractive eye care practice, we would recommend fully correcting the 
refractive error with a multifocal soft contact lens design or recommending orthokeratology.  The 
Proclear Multifocal (CooperVision) “D” design, with a +2.00D add, is the only standard commercial 
lens published on to date [8]. Orthokeratology is a convenient option providing the patient with 
spectacle/contact lens-free vision during the day, however, it is more effective in patients with mild-
moderate levels of myopia. In combination with myopia control intervention therapy, all patients 
should be advised to maximise time spent outdoors. 
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